Details for New Drug Application (NDA): 212595
✉ Email this page to a colleague
NDA 212595 describes RIOMET ER, which is a drug marketed by Sun Pharm and is included in one NDA. There is one patent protecting this drug. Additional details are available on the RIOMET ER profile page.
The generic ingredient in RIOMET ER is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.
The generic ingredient in RIOMET ER is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.
Summary for 212595
| Tradename: | RIOMET ER |
| Applicant: | Sun Pharm |
| Ingredient: | metformin hydrochloride |
| Patents: | 1 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 212595
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION, EXTENDED RELEASE;ORAL | Strength | 500MG/5ML | ||||
| Approval Date: | Aug 29, 2019 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | May 1, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
